Open AccessDolutegravir plus rilpivirine: benefits beyond viral suppression
Author(s) -
Jesús Troya,
Carlos Dueñas,
Idoia Irazola,
Ignacio Santos,
Sara de la Fuente,
Desiré Gil,
Cristina Hernández,
Marı́a José Galindo,
Julia Gómez,
Elisabeth Delgado,
Estela Moreno-García,
Guillermo Gamba Posada,
Teresa Aldámiz,
José Antonio Iribarren,
José Antonio Iglesias Guerra,
Miguel Ángel Morán,
Carlos Galera,
Javier de la Fuente,
Ana Peláez,
Miguel Cervero,
María Ángeles Garcinuño,
Marta Montero,
Francisco Ceballos,
L Buzón
Publication year - 2022
Publication title -
medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000029252
Subject(s) - medicine , dolutegravir , rilpivirine , cd8 , cd4 cd8 ratio , retrospective cohort study , coinfection , cohort , population , viral load , gastroenterology , antiretroviral therapy , human immunodeficiency virus (hiv) , immunology , immune system , lymphocyte subsets , environmental health